- Home
- TFX vs LNTH Comparison
TFX vs LNTH Comparison
Compare TFX & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFX
- LNTH
- Stock Information
- Founded
- TFX 1943
- LNTH 1956
- Country
- TFX United States
- LNTH United States
- Employees
- TFX N/A
- LNTH N/A
- Industry
- TFX Medical/Dental Instruments
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TFX Health Care
- LNTH Health Care
- Exchange
- TFX Nasdaq
- LNTH Nasdaq
- Market Cap
- TFX 9.0B
- LNTH 7.2B
- IPO Year
- TFX N/A
- LNTH 2015
- Fundamental
- Price
- TFX $190.79
- LNTH $90.52
- Analyst Decision
- TFX Buy
- LNTH Strong Buy
- Analyst Count
- TFX 9
- LNTH 7
- Target Price
- TFX $259.00
- LNTH $121.86
- AVG Volume (30 Days)
- TFX 549.1K
- LNTH 1.6M
- Earning Date
- TFX 10-31-2024
- LNTH 11-06-2024
- Dividend Yield
- TFX 0.71%
- LNTH N/A
- EPS Growth
- TFX N/A
- LNTH 304.57
- EPS
- TFX 5.03
- LNTH 6.02
- Revenue
- TFX $3,025,824,000.00
- LNTH $1,496,799,000.00
- Revenue This Year
- TFX $4.52
- LNTH $19.56
- Revenue Next Year
- TFX $4.92
- LNTH $6.32
- P/E Ratio
- TFX $38.13
- LNTH $15.03
- Revenue Growth
- TFX 2.27
- LNTH 24.15
- 52 Week Low
- TFX $185.66
- LNTH $50.20
- 52 Week High
- TFX $257.85
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- TFX 33.43
- LNTH 45.56
- Support Level
- TFX $185.66
- LNTH $75.00
- Resistance Level
- TFX $195.47
- LNTH $118.21
- Average True Range (ATR)
- TFX 4.83
- LNTH 5.13
- MACD
- TFX 0.16
- LNTH 0.13
- Stochastic Oscillator
- TFX 29.74
- LNTH 38.71
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.